Heart Failure Clinical Trial
TRANSFORM-HF Ancillary Mechanistic Study
Summary
Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.
Full Description
Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week) after hospital discharge.
Eligibility Criteria
Inclusion Criteria:
Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide
Willing to provide blood and urine sample at enrollment and follow-up
Exclusion Criteria:
Inability or unwillingness to comply with the study requirements
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
New Haven Connecticut, 06510, United States
New Orleans Louisiana, 70121, United States
Baltimore Maryland, 21201, United States
Minneapolis Minnesota, 55455, United States
Manhasset New York, 11030, United States
Durham North Carolina, 27710, United States
Falls Church Virginia, 22042, United States
Norfolk Virginia, 23507, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.